CJC-1295 With DAC + Ipamorelin + GHRP-2 Blend Vials
|CJC – 1295 DAC Peptide|
|Molar Mass||3367.954 g·mol−1|
|IUPAC Name||CJC 1295 (DAC-GRF)|
|Molar Mass||711.868 g·mol−1|
|Molar Mass||817.992 g·mol−1|
The CJC-1295 With DAC + Ipamorelin + GHRP-2 Blend is a research formulation designed exclusively for scientific investigations. This blend combines CJC-1295 With DAC, Ipamorelin, and GHRP-2, offering a multifaceted approach to research on growth hormone-related processes.
CJC-1295 With DAC is known for its extended half-life, potentially leading to prolonged effects on growth hormone release. Ipamorelin is recognized for its ability to stimulate growth hormone secretion, potentially influencing various physiological functions. GHRP-2 is a peptide that may stimulate the release of growth hormone, contributing to research on muscle growth and other related aspects.
This research blend is formulated for scientific exploration into growth hormone-related processes. Researchers may investigate its applications in diverse research models to gain insights into the synergistic effects of its components.
Potential Synergistic Benefits
Researchers may explore the combined effects of CJC-1295 With DAC, Ipamorelin, and GHRP-2, assessing potential synergies that could enhance the understanding of growth hormone regulation.
CJC-1295 and IGF-1
Studies may focus on the interplay between CJC-1295 With DAC and insulin-like growth factor 1 (IGF-1), exploring potential implications for growth-related processes.
Ipamorelin and Weight Gain
Research may investigate the role of Ipamorelin in influencing weight gain, contributing to a comprehensive understanding of its impact on body composition.
GHRP-2 May Improve Muscle Growth
Researchers may explore the potential of GHRP-2 to enhance muscle growth, providing valuable insights into its applications in muscle-related research.
The CJC-1295 With DAC + Ipamorelin + GHRP-2 Blend is a research formulation offering a comprehensive approach to the study of growth hormone-related processes. Researchers are encouraged to explore its potential synergistic benefits and individual contributions to gain a deeper understanding.
- Yamamoto D, Ikeshita N, Matsubara T, Tasaki H, Herningtyas EH, Toda K, Iida K, Takahashi Y, Kaji H, Chihara K, Okimura Y. GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1. Life Sci. 2008 Feb 27;82(9-10):460-6. doi: 10.1016/j.lfs.2007.11.019. Epub 2007 Dec 5. PMID: 18191156. [Read More].
- Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001 Jan 12;280(1):132-8. doi: 10.1006/bbrc.2000.4065. PMID: 11162489. [Read More].
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683. [Read More].